Literature DB >> 7665243

Interphase cytogenetic analysis of erbB2 and topoII alpha co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ.

D S Murphy1, P McHardy, J Coutts, E A Mallon, W D George, S B Kaye, R Brown, W N Keith.   

Abstract

Breast cancer is a genetically complex disease. Fluorescence in situ hybridisation can be used to analyse the genetics of breast-cancer progression in interphase cytogenetics. We have analysed the histological distribution of erbB2 and topoll alpha co-amplification in paraffin sections of invasive breast cancer and show that the co-amplified loci share the same histological distribution in the tumour and have a similar nuclear distribution within individual nuclei. Regions of the tumours without amplification are easily recognized and tumours with erbB2 and topoll alpha co-amplification can be distinguished from those with erbB2 amplification alone. In addition, FISH was used to show polysomy of chromosome 17 in non-invasive ductal carcinoma in situ of the breast and erbB2 amplification in both the invasive and non-invasive components of a breast cancer biopsy. This report of an interphase cytogenetic analysis of non-invasive breast carcinoma in situ demonstrates the usefulness of FISH for the genetic study of breast cancer progression.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7665243     DOI: 10.1002/ijc.2910640106

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  15 in total

1.  Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.

Authors:  Michael F Press; Guido Sauter; Marc Buyse; Leslie Bernstein; Roberta Guzman; Angela Santiago; Ivonne E Villalobos; Wolfgang Eiermann; Tadeusz Pienkowski; Miguel Martin; Nicholas Robert; John Crown; Valerie Bee; Henry Taupin; Kerry J Flom; Isabelle Tabah-Fisch; Giovanni Pauletti; Mary-Ann Lindsay; Alessandro Riva; Dennis J Slamon
Journal:  J Clin Oncol       Date:  2010-12-28       Impact factor: 44.544

2.  Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer.

Authors:  T A Järvinen; M Tanner; V Rantanen; M Bärlund; A Borg; S Grénman; J Isola
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

3.  Genetic heterogeneity of primary and metastatic breast carcinoma defined by fluorescence in situ hybridization.

Authors:  J F Simpson; D E Quan; J P Ho; M L Slovak
Journal:  Am J Pathol       Date:  1996-09       Impact factor: 4.307

Review 4.  Genome evolution in ductal carcinoma in situ: invasion of the clones.

Authors:  Anna K Casasent; Mary Edgerton; Nicholas E Navin
Journal:  J Pathol       Date:  2016-11-27       Impact factor: 7.996

5.  Amplification of fluorescent in situ hybridisation signals in formalin fixed paraffin wax embedded sections of colon tumour using biotinylated tyramide.

Authors:  J A McKay; G I Murray; W N Keith; H L McLeod
Journal:  Mol Pathol       Date:  1997-12

6.  Mutation of the TP53 gene and allelic imbalance at chromosome 17p13 in ductal carcinoma in situ.

Authors:  K E Munn; R A Walker; L Menasce; J M Varley
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

7.  Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity.

Authors:  H L McLeod; W N Keith
Journal:  Br J Cancer       Date:  1996-08       Impact factor: 7.640

Review 8.  Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response.

Authors:  Monica M Reinholz; Amy K Bruzek; Daniel W Visscher; Wilma L Lingle; Matthew J Schroeder; Edith A Perez; Robert B Jenkins
Journal:  Lancet Oncol       Date:  2009-03       Impact factor: 41.316

9.  Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.

Authors:  T A Järvinen; K Holli; T Kuukasjärvi; J J Isola
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

10.  Is chromosome 9 loss a marker of disease recurrence in transitional cell carcinoma of the urinary bladder?

Authors:  J M Bartlett; A D Watters; S A Ballantyne; J J Going; K M Grigor; T G Cooke
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.